Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,908
archived clinical trials in
Renal Impairment / Chronic Kidney Disease

Safety & Efficacy of Certican in Pediatric de Novo Renal Transplant Patients
Multicenter Trial of the Safety & Efficacy of Certican in Pediatric de Novo Renal Transplant Patients
Status: Archived
Columbus Children's Research Institute
mi
from
Columbus, OH
Safety & Efficacy of Certican in Pediatric de Novo Renal Transplant Patients
Multicenter Trial of the Safety & Efficacy of Certican in Pediatric de Novo Renal Transplant Patients
Status: Archived
Updated: 1/1/1970
Columbus Children's Research Institute
mi
from
Columbus, OH
Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
Bone Histomorphometry Assessment For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
Status: Archived
Clinical Research Facility
mi
from
Phoenix, AZ
Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
Bone Histomorphometry Assessment For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Phoenix, AZ
Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
Bone Histomorphometry Assessment For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
Status: Archived
Clinical Research Facility
mi
from
San Diego, CA
Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
Bone Histomorphometry Assessment For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
San Diego, CA
Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
Bone Histomorphometry Assessment For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
Status: Archived
Clinical Research Facility
mi
from
Denver, CO
Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
Bone Histomorphometry Assessment For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Denver, CO
Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
Bone Histomorphometry Assessment For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
Status: Archived
Clinical Research Facility
mi
from
New Haven, CT
Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
Bone Histomorphometry Assessment For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
New Haven, CT
Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
Bone Histomorphometry Assessment For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
Status: Archived
Clinical Research Facility
mi
from
Fort Lauderdale, FL
Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
Bone Histomorphometry Assessment For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Fort Lauderdale, FL
Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
Bone Histomorphometry Assessment For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
Status: Archived
Clinical Research Facility
mi
from
Evanston, IL
Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
Bone Histomorphometry Assessment For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Evanston, IL
Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
Bone Histomorphometry Assessment For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
Status: Archived
Clinical Research Facility
mi
from
New Orleans, LA
Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
Bone Histomorphometry Assessment For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
New Orleans, LA
Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
Bone Histomorphometry Assessment For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
Status: Archived
Clinical Research Facility
mi
from
Baltimore, MD
Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
Bone Histomorphometry Assessment For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Baltimore, MD
Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
Bone Histomorphometry Assessment For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
Status: Archived
Clinical Research Facility
mi
from
St Louis, MO
Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
Bone Histomorphometry Assessment For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
St Louis, MO
Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
Bone Histomorphometry Assessment For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
Status: Archived
Clinical Research Facility
mi
from
Teaneck, NJ
Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
Bone Histomorphometry Assessment For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Teaneck, NJ
Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
Bone Histomorphometry Assessment For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
Status: Archived
Clinical Research Facility
mi
from
Bronx, NY
Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
Bone Histomorphometry Assessment For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Bronx, NY
Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
Bone Histomorphometry Assessment For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
Status: Archived
Clinical Research Facility
mi
from
Allentown, PA
Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
Bone Histomorphometry Assessment For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Allentown, PA
Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
Bone Histomorphometry Assessment For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
Status: Archived
Clinical Research Facility
mi
from
Houston, TX
Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
Bone Histomorphometry Assessment For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Houston, TX
T Wave Alternans in Hemodialysis
Pilot Study of a Noninvasive Predictor of Sudden Cardiac Death in Hemodialysis Patients
Status: Archived
Indiana Univeristy School of Medicine
mi
from
Indianapolis, IN
T Wave Alternans in Hemodialysis
Pilot Study of a Noninvasive Predictor of Sudden Cardiac Death in Hemodialysis Patients
Status: Archived
Updated: 1/1/1970
Indiana Univeristy School of Medicine
mi
from
Indianapolis, IN
Rituximab in Kidney Transplantation
B-Cell Depletion by Anti-CD20 (Rituximab) in Renal Allograft Recipients Who Develop Early de Novo Anti-HLA Alloantibodies
Status: Archived
University of Alabama - Burmingham
mi
from
Birmingham, AL
Rituximab in Kidney Transplantation
B-Cell Depletion by Anti-CD20 (Rituximab) in Renal Allograft Recipients Who Develop Early de Novo Anti-HLA Alloantibodies
Status: Archived
Updated: 1/1/1970
University of Alabama - Burmingham
mi
from
Birmingham, AL
Rituximab in Kidney Transplantation
B-Cell Depletion by Anti-CD20 (Rituximab) in Renal Allograft Recipients Who Develop Early de Novo Anti-HLA Alloantibodies
Status: Archived
Unversity of California, San Francisco
mi
from
San Francisco, CA
Rituximab in Kidney Transplantation
B-Cell Depletion by Anti-CD20 (Rituximab) in Renal Allograft Recipients Who Develop Early de Novo Anti-HLA Alloantibodies
Status: Archived
Updated: 1/1/1970
Unversity of California, San Francisco
mi
from
San Francisco, CA
Rituximab in Kidney Transplantation
B-Cell Depletion by Anti-CD20 (Rituximab) in Renal Allograft Recipients Who Develop Early de Novo Anti-HLA Alloantibodies
Status: Archived
University of Florida Gainesville
mi
from
Gainesville, FL
Rituximab in Kidney Transplantation
B-Cell Depletion by Anti-CD20 (Rituximab) in Renal Allograft Recipients Who Develop Early de Novo Anti-HLA Alloantibodies
Status: Archived
Updated: 1/1/1970
University of Florida Gainesville
mi
from
Gainesville, FL
Rituximab in Kidney Transplantation
B-Cell Depletion by Anti-CD20 (Rituximab) in Renal Allograft Recipients Who Develop Early de Novo Anti-HLA Alloantibodies
Status: Archived
Northwestern University
mi
from
Chicago, IL
Rituximab in Kidney Transplantation
B-Cell Depletion by Anti-CD20 (Rituximab) in Renal Allograft Recipients Who Develop Early de Novo Anti-HLA Alloantibodies
Status: Archived
Updated: 1/1/1970
Northwestern University
mi
from
Chicago, IL
Rituximab in Kidney Transplantation
B-Cell Depletion by Anti-CD20 (Rituximab) in Renal Allograft Recipients Who Develop Early de Novo Anti-HLA Alloantibodies
Status: Archived
University of Illinois College of Medicine
mi
from
Chicago, IL
Rituximab in Kidney Transplantation
B-Cell Depletion by Anti-CD20 (Rituximab) in Renal Allograft Recipients Who Develop Early de Novo Anti-HLA Alloantibodies
Status: Archived
Updated: 1/1/1970
University of Illinois College of Medicine
mi
from
Chicago, IL
Rituximab in Kidney Transplantation
B-Cell Depletion by Anti-CD20 (Rituximab) in Renal Allograft Recipients Who Develop Early de Novo Anti-HLA Alloantibodies
Status: Archived
Maine Children's Medical Center
mi
from
Portland, ME
Rituximab in Kidney Transplantation
B-Cell Depletion by Anti-CD20 (Rituximab) in Renal Allograft Recipients Who Develop Early de Novo Anti-HLA Alloantibodies
Status: Archived
Updated: 1/1/1970
Maine Children's Medical Center
mi
from
Portland, ME
Rituximab in Kidney Transplantation
B-Cell Depletion by Anti-CD20 (Rituximab) in Renal Allograft Recipients Who Develop Early de Novo Anti-HLA Alloantibodies
Status: Archived
Johns Hopkins University
mi
from
Baltimore, MD
Rituximab in Kidney Transplantation
B-Cell Depletion by Anti-CD20 (Rituximab) in Renal Allograft Recipients Who Develop Early de Novo Anti-HLA Alloantibodies
Status: Archived
Updated: 1/1/1970
Johns Hopkins University
mi
from
Baltimore, MD
Rituximab in Kidney Transplantation
B-Cell Depletion by Anti-CD20 (Rituximab) in Renal Allograft Recipients Who Develop Early de Novo Anti-HLA Alloantibodies
Status: Archived
University of Maryland, Baltimore
mi
from
Baltimore, MD
Rituximab in Kidney Transplantation
B-Cell Depletion by Anti-CD20 (Rituximab) in Renal Allograft Recipients Who Develop Early de Novo Anti-HLA Alloantibodies
Status: Archived
Updated: 1/1/1970
University of Maryland, Baltimore
mi
from
Baltimore, MD
Rituximab in Kidney Transplantation
B-Cell Depletion by Anti-CD20 (Rituximab) in Renal Allograft Recipients Who Develop Early de Novo Anti-HLA Alloantibodies
Status: Archived
Brigham & Women's Hospital Women's Health Center
mi
from
Chestnut Hill, MA
Rituximab in Kidney Transplantation
B-Cell Depletion by Anti-CD20 (Rituximab) in Renal Allograft Recipients Who Develop Early de Novo Anti-HLA Alloantibodies
Status: Archived
Updated: 1/1/1970
Brigham & Women's Hospital Women's Health Center
mi
from
Chestnut Hill, MA
Rituximab in Kidney Transplantation
B-Cell Depletion by Anti-CD20 (Rituximab) in Renal Allograft Recipients Who Develop Early de Novo Anti-HLA Alloantibodies
Status: Archived
Massachusetts General Hospital
mi
from
Boston, MA
Rituximab in Kidney Transplantation
B-Cell Depletion by Anti-CD20 (Rituximab) in Renal Allograft Recipients Who Develop Early de Novo Anti-HLA Alloantibodies
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
mi
from
Boston, MA
Rituximab in Kidney Transplantation
B-Cell Depletion by Anti-CD20 (Rituximab) in Renal Allograft Recipients Who Develop Early de Novo Anti-HLA Alloantibodies
Status: Archived
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Rituximab in Kidney Transplantation
B-Cell Depletion by Anti-CD20 (Rituximab) in Renal Allograft Recipients Who Develop Early de Novo Anti-HLA Alloantibodies
Status: Archived
Updated: 1/1/1970
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Rituximab in Kidney Transplantation
B-Cell Depletion by Anti-CD20 (Rituximab) in Renal Allograft Recipients Who Develop Early de Novo Anti-HLA Alloantibodies
Status: Archived
Children's Hospital - Boston
mi
from
Boston, MA
Rituximab in Kidney Transplantation
B-Cell Depletion by Anti-CD20 (Rituximab) in Renal Allograft Recipients Who Develop Early de Novo Anti-HLA Alloantibodies
Status: Archived
Updated: 1/1/1970
Children's Hospital - Boston
mi
from
Boston, MA
Rituximab in Kidney Transplantation
B-Cell Depletion by Anti-CD20 (Rituximab) in Renal Allograft Recipients Who Develop Early de Novo Anti-HLA Alloantibodies
Status: Archived
Saint Barnabas Medical Center
mi
from
West Orange, NJ
Rituximab in Kidney Transplantation
B-Cell Depletion by Anti-CD20 (Rituximab) in Renal Allograft Recipients Who Develop Early de Novo Anti-HLA Alloantibodies
Status: Archived
Updated: 1/1/1970
Saint Barnabas Medical Center
mi
from
West Orange, NJ
Rituximab in Kidney Transplantation
B-Cell Depletion by Anti-CD20 (Rituximab) in Renal Allograft Recipients Who Develop Early de Novo Anti-HLA Alloantibodies
Status: Archived
Oregon Health Science University
mi
from
Portland, OR
Rituximab in Kidney Transplantation
B-Cell Depletion by Anti-CD20 (Rituximab) in Renal Allograft Recipients Who Develop Early de Novo Anti-HLA Alloantibodies
Status: Archived
Updated: 1/1/1970
Oregon Health Science University
mi
from
Portland, OR
Rituximab in Kidney Transplantation
B-Cell Depletion by Anti-CD20 (Rituximab) in Renal Allograft Recipients Who Develop Early de Novo Anti-HLA Alloantibodies
Status: Archived
Legacy Transplant Services
mi
from
Portland, OR
Rituximab in Kidney Transplantation
B-Cell Depletion by Anti-CD20 (Rituximab) in Renal Allograft Recipients Who Develop Early de Novo Anti-HLA Alloantibodies
Status: Archived
Updated: 1/1/1970
Legacy Transplant Services
mi
from
Portland, OR
Rituximab in Kidney Transplantation
B-Cell Depletion by Anti-CD20 (Rituximab) in Renal Allograft Recipients Who Develop Early de Novo Anti-HLA Alloantibodies
Status: Archived
Children's Hospital at Downstate
mi
from
Brooklyn, NY
Rituximab in Kidney Transplantation
B-Cell Depletion by Anti-CD20 (Rituximab) in Renal Allograft Recipients Who Develop Early de Novo Anti-HLA Alloantibodies
Status: Archived
Updated: 1/1/1970
Children's Hospital at Downstate
mi
from
Brooklyn, NY
Rituximab in Kidney Transplantation
B-Cell Depletion by Anti-CD20 (Rituximab) in Renal Allograft Recipients Who Develop Early de Novo Anti-HLA Alloantibodies
Status: Archived
Houston Methodist Hospital
mi
from
Houston, TX
Rituximab in Kidney Transplantation
B-Cell Depletion by Anti-CD20 (Rituximab) in Renal Allograft Recipients Who Develop Early de Novo Anti-HLA Alloantibodies
Status: Archived
Updated: 1/1/1970
Houston Methodist Hospital
mi
from
Houston, TX
Rituximab in Kidney Transplantation
B-Cell Depletion by Anti-CD20 (Rituximab) in Renal Allograft Recipients Who Develop Early de Novo Anti-HLA Alloantibodies
Status: Archived
Children's Hospital
mi
from
Pittsburgh, PA
Rituximab in Kidney Transplantation
B-Cell Depletion by Anti-CD20 (Rituximab) in Renal Allograft Recipients Who Develop Early de Novo Anti-HLA Alloantibodies
Status: Archived
Updated: 1/1/1970
Children's Hospital
mi
from
Pittsburgh, PA
Study Comparing Effect On Carotid Atherosclerosis Following Conversion From Tacrolimus To Sirolimus Post-Transplant In Kidney Transplant Patients
A Prospective, Randomized, Open-Label, Pilot Study To Compare The Effect On Carotid Atherosclerosis Of A Tacrolimus-Based Regimen With Conversion From A Tacrolimus- To A Sirolimus-Based Regimen At 3-4 Months Post-Transplant In De Novo Renal Transplant Recipients
Status: Archived
Massachusetts General Hospital
mi
from
Boston, MA
Study Comparing Effect On Carotid Atherosclerosis Following Conversion From Tacrolimus To Sirolimus Post-Transplant In Kidney Transplant Patients
A Prospective, Randomized, Open-Label, Pilot Study To Compare The Effect On Carotid Atherosclerosis Of A Tacrolimus-Based Regimen With Conversion From A Tacrolimus- To A Sirolimus-Based Regimen At 3-4 Months Post-Transplant In De Novo Renal Transplant Recipients
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
mi
from
Boston, MA
Effects Of Darbepoetin On Vascular Repair Mechanisms In Kidney Disease The DARBEPC Study
Effects Of Darbepoetin On Vascular Repair Mechanisms In Kidney Disease The DARBEPC Study
Status: Archived
University of Michigan Health Systems
mi
from
Ann Arbor, MI
Effects Of Darbepoetin On Vascular Repair Mechanisms In Kidney Disease The DARBEPC Study
Effects Of Darbepoetin On Vascular Repair Mechanisms In Kidney Disease The DARBEPC Study
Status: Archived
Updated: 1/1/1970
University of Michigan Health Systems
mi
from
Ann Arbor, MI
Evaluating Patients With Varying Degrees of Renal Function
A Phase I, Open-Label Study Evaluating the Pharmacokinetics of Components of S-1 in Patients With Varying Degrees of Renal Function
Status: Archived
Premiere Oncology of Arizona
mi
from
Scottsdale, AZ
Evaluating Patients With Varying Degrees of Renal Function
A Phase I, Open-Label Study Evaluating the Pharmacokinetics of Components of S-1 in Patients With Varying Degrees of Renal Function
Status: Archived
Updated: 1/1/1970
Premiere Oncology of Arizona
mi
from
Scottsdale, AZ
Evaluating Patients With Varying Degrees of Renal Function
A Phase I, Open-Label Study Evaluating the Pharmacokinetics of Components of S-1 in Patients With Varying Degrees of Renal Function
Status: Archived
USC Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Evaluating Patients With Varying Degrees of Renal Function
A Phase I, Open-Label Study Evaluating the Pharmacokinetics of Components of S-1 in Patients With Varying Degrees of Renal Function
Status: Archived
Updated: 1/1/1970
USC Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Evaluating Patients With Varying Degrees of Renal Function
A Phase I, Open-Label Study Evaluating the Pharmacokinetics of Components of S-1 in Patients With Varying Degrees of Renal Function
Status: Archived
Premier Oncology Group
mi
from
Scottsdale, AZ
Evaluating Patients With Varying Degrees of Renal Function
A Phase I, Open-Label Study Evaluating the Pharmacokinetics of Components of S-1 in Patients With Varying Degrees of Renal Function
Status: Archived
Updated: 1/1/1970
Premier Oncology Group
mi
from
Scottsdale, AZ
Evaluating Patients With Varying Degrees of Renal Function
A Phase I, Open-Label Study Evaluating the Pharmacokinetics of Components of S-1 in Patients With Varying Degrees of Renal Function
Status: Archived
Yale University School of Medicine
mi
from
New Haven, CT
Evaluating Patients With Varying Degrees of Renal Function
A Phase I, Open-Label Study Evaluating the Pharmacokinetics of Components of S-1 in Patients With Varying Degrees of Renal Function
Status: Archived
Updated: 1/1/1970
Yale University School of Medicine
mi
from
New Haven, CT
Evaluating Patients With Varying Degrees of Renal Function
A Phase I, Open-Label Study Evaluating the Pharmacokinetics of Components of S-1 in Patients With Varying Degrees of Renal Function
Status: Archived
University of Kentucky Hospital
mi
from
Lexington, KY
Evaluating Patients With Varying Degrees of Renal Function
A Phase I, Open-Label Study Evaluating the Pharmacokinetics of Components of S-1 in Patients With Varying Degrees of Renal Function
Status: Archived
Updated: 1/1/1970
University of Kentucky Hospital
mi
from
Lexington, KY
Evaluating Patients With Varying Degrees of Renal Function
A Phase I, Open-Label Study Evaluating the Pharmacokinetics of Components of S-1 in Patients With Varying Degrees of Renal Function
Status: Archived
University of Maryland, Baltimore
mi
from
Baltimore, MD
Evaluating Patients With Varying Degrees of Renal Function
A Phase I, Open-Label Study Evaluating the Pharmacokinetics of Components of S-1 in Patients With Varying Degrees of Renal Function
Status: Archived
Updated: 1/1/1970
University of Maryland, Baltimore
mi
from
Baltimore, MD
Evaluating Patients With Varying Degrees of Renal Function
A Phase I, Open-Label Study Evaluating the Pharmacokinetics of Components of S-1 in Patients With Varying Degrees of Renal Function
Status: Archived
Washington University
mi
from
St. Louis, MO
Evaluating Patients With Varying Degrees of Renal Function
A Phase I, Open-Label Study Evaluating the Pharmacokinetics of Components of S-1 in Patients With Varying Degrees of Renal Function
Status: Archived
Updated: 1/1/1970
Washington University
mi
from
St. Louis, MO
Evaluating Patients With Varying Degrees of Renal Function
A Phase I, Open-Label Study Evaluating the Pharmacokinetics of Components of S-1 in Patients With Varying Degrees of Renal Function
Status: Archived
Cancer Research & Treatment Center/University of New Mexico
mi
from
Albuquerque, NM
Evaluating Patients With Varying Degrees of Renal Function
A Phase I, Open-Label Study Evaluating the Pharmacokinetics of Components of S-1 in Patients With Varying Degrees of Renal Function
Status: Archived
Updated: 1/1/1970
Cancer Research & Treatment Center/University of New Mexico
mi
from
Albuquerque, NM
Evaluating Patients With Varying Degrees of Renal Function
A Phase I, Open-Label Study Evaluating the Pharmacokinetics of Components of S-1 in Patients With Varying Degrees of Renal Function
Status: Archived
The Institute for Drug Development
mi
from
San Antonio, TX
Evaluating Patients With Varying Degrees of Renal Function
A Phase I, Open-Label Study Evaluating the Pharmacokinetics of Components of S-1 in Patients With Varying Degrees of Renal Function
Status: Archived
Updated: 1/1/1970
The Institute for Drug Development
mi
from
San Antonio, TX
Low Phosphate Diets in Patients With Early Stages of Chronic Kidney Disease
Reduced Phosphate Intake in "Normo-Phosphatemic" Chronic Kidney Disease Patients
Status: Archived
Massachusetts General Hospital
mi
from
Boston, MA
Low Phosphate Diets in Patients With Early Stages of Chronic Kidney Disease
Reduced Phosphate Intake in "Normo-Phosphatemic" Chronic Kidney Disease Patients
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
mi
from
Boston, MA
Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease
An Open Label, Four Week, Dose Escalating Pharmacokinetic, Pharmacodynamic, Efficacy and Safety Study of CTA018 Injection in Subjects With Stage 5 Chronic Kidney Disease With Secondary Hyperparathyroidism on Hemodialysis
Status: Archived
Pines Clinical Research, Inc.
mi
from
Pembroke Pines, FL
Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease
An Open Label, Four Week, Dose Escalating Pharmacokinetic, Pharmacodynamic, Efficacy and Safety Study of CTA018 Injection in Subjects With Stage 5 Chronic Kidney Disease With Secondary Hyperparathyroidism on Hemodialysis
Status: Archived
Updated: 1/1/1970
Pines Clinical Research, Inc.
mi
from
Pembroke Pines, FL
Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease
An Open Label, Four Week, Dose Escalating Pharmacokinetic, Pharmacodynamic, Efficacy and Safety Study of CTA018 Injection in Subjects With Stage 5 Chronic Kidney Disease With Secondary Hyperparathyroidism on Hemodialysis
Status: Archived
Boise Kidney and Hypertension Institute
mi
from
Meridian, ID
Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease
An Open Label, Four Week, Dose Escalating Pharmacokinetic, Pharmacodynamic, Efficacy and Safety Study of CTA018 Injection in Subjects With Stage 5 Chronic Kidney Disease With Secondary Hyperparathyroidism on Hemodialysis
Status: Archived
Updated: 1/1/1970
Boise Kidney and Hypertension Institute
mi
from
Meridian, ID
Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease
An Open Label, Four Week, Dose Escalating Pharmacokinetic, Pharmacodynamic, Efficacy and Safety Study of CTA018 Injection in Subjects With Stage 5 Chronic Kidney Disease With Secondary Hyperparathyroidism on Hemodialysis
Status: Archived
Western New England Renal & Transplant Associates (WNERTA)
mi
from
Springfield, MA
Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease
An Open Label, Four Week, Dose Escalating Pharmacokinetic, Pharmacodynamic, Efficacy and Safety Study of CTA018 Injection in Subjects With Stage 5 Chronic Kidney Disease With Secondary Hyperparathyroidism on Hemodialysis
Status: Archived
Updated: 1/1/1970
Western New England Renal & Transplant Associates (WNERTA)
mi
from
Springfield, MA
Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease
An Open Label, Four Week, Dose Escalating Pharmacokinetic, Pharmacodynamic, Efficacy and Safety Study of CTA018 Injection in Subjects With Stage 5 Chronic Kidney Disease With Secondary Hyperparathyroidism on Hemodialysis
Status: Archived
Southeast Renal Research Institute
mi
from
Chattanooga, TN
Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease
An Open Label, Four Week, Dose Escalating Pharmacokinetic, Pharmacodynamic, Efficacy and Safety Study of CTA018 Injection in Subjects With Stage 5 Chronic Kidney Disease With Secondary Hyperparathyroidism on Hemodialysis
Status: Archived
Updated: 1/1/1970
Southeast Renal Research Institute
mi
from
Chattanooga, TN
Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease
An Open Label, Four Week, Dose Escalating Pharmacokinetic, Pharmacodynamic, Efficacy and Safety Study of CTA018 Injection in Subjects With Stage 5 Chronic Kidney Disease With Secondary Hyperparathyroidism on Hemodialysis
Status: Archived
U.S. Renal Care
mi
from
Fort Worth, TX
Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease
An Open Label, Four Week, Dose Escalating Pharmacokinetic, Pharmacodynamic, Efficacy and Safety Study of CTA018 Injection in Subjects With Stage 5 Chronic Kidney Disease With Secondary Hyperparathyroidism on Hemodialysis
Status: Archived
Updated: 1/1/1970
U.S. Renal Care
mi
from
Fort Worth, TX